{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lurbinectedin+%28PM01183%29", "query": { "intervention": "lurbinectedin (PM01183)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lurbinectedin+%28PM01183%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T12:35:27.895Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05734066", "title": "Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Ewing Sarcoma", "Relapsed Ewing Sarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 60, "start_date": "2023-05-23", "completion_date": "2028-04-20", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05734066" }, { "nct_id": "NCT01314599", "title": "Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemia" ], "interventions": [ { "name": "PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2011-05", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01314599" }, { "nct_id": "NCT05153239", "title": "Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Small Cell Lung Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 705, "start_date": "2022-07-22", "completion_date": "2026-04-10", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 15, "location_summary": "Chandler, Arizona • Hot Springs, Arkansas • Fort Myers, Florida + 12 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153239" }, { "nct_id": "NCT07365241", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "ABBV-706", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Amrubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 531, "start_date": "2026-07-02", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07365241" }, { "nct_id": "NCT02566993", "title": "Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small-cell Lung Cancer" ], "interventions": [ { "name": "Lurbinectedin (PM01183)", "type": "DRUG" }, { "name": "Doxorubicin (DOX)", "type": "DRUG" }, { "name": "Cyclophosphamide (CTX)", "type": "DRUG" }, { "name": "Vincristine (VCR)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2016-08-30", "completion_date": "2020-02-24", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Fullerton, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02566993" }, { "nct_id": "NCT02421588", "title": "Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Lurbinectedin (PM01183)", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 442, "start_date": "2015-05", "completion_date": "2018-10-12", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 28, "location_summary": "Peoria, Arizona • Greenbrae, California • La Jolla, California + 23 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02421588" }, { "nct_id": "NCT01831089", "title": "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Gynecological Cancer", "Head and Neck Carcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Non-squamous Cell Lung Cancer" ], "interventions": [ { "name": "PM01183 + paclitaxel +/- bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2013-09", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831089" }, { "nct_id": "NCT02448537", "title": "A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Sarcoma" ], "interventions": [ { "name": "PM01183", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2015-08", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02448537" }, { "nct_id": "NCT01525589", "title": "A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PM01183", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 111, "start_date": "2012-06-13", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 5, "location_summary": "Stanford, California • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525589" }, { "nct_id": "NCT04802174", "title": "Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "SCLC", "Small Cell Cancer", "Advanced Solid Tumor", "High Grade Neuroendocrine Cancers" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Berzosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-06-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-01T12:35:27.895Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04802174" } ] }